Literature DB >> 1410576

The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.

N J Slevin1, J H Hendry, S A Roberts, A Agren-Cronqvist.   

Abstract

Local control of cancer by radiotherapy may be prejudiced by accelerated tumour clonogen repopulation particularly during protracted treatment schedules. A series of 496 cases of T2 and T3 larynx cancer treated here by radiotherapy has been studied to examine the impact on local control of treatment durations ranging from 9 to 41 days. Data were analysed using a linear-quadratic formulation describing the fractionation sensitivity, with the incorporation of a parameter relating to treatment time. Using combined T2 and T3 data, the increase in dose required to maintain a constant local control (the time factor) was between 0.5 and 0.6 Gy per day. These values are similar to those reported for 4 weeks or more in the literature. Also, the calculated dose to control 50% of tumours, given over the standard Christie duration of 21 days, was on the line projected back from literature data over 28-66 days. The present data are consistent with the presence of such a time factor following a lag phase of not more than 3 weeks after starting radiotherapy. Hence, further consideration should be given to using shorter overall treatment times in radiotherapy for head and neck cancer.

Entities:  

Mesh:

Year:  1992        PMID: 1410576     DOI: 10.1016/0167-8140(92)90226-k

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.

Authors:  Mary E Platek; Susan A McCloskey; Myra Cruz; Mark S Burke; Mary E Reid; Gregory E Wilding; Nestor R Rigual; Saurin R Popat; Thom R Loree; Vishal Gupta; Graham W Warren; Maureen Sullivan; Wesley L Hicks; Anurag K Singh
Journal:  Head Neck       Date:  2012-05-22       Impact factor: 3.147

Review 2.  A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: part 1.

Authors:  H Jawad; N A Hodson; P J Nixon
Journal:  Br Dent J       Date:  2015-01       Impact factor: 1.626

Review 3.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

4.  Conventional fractionation should not be the standard of care for T2 glottic cancer.

Authors:  Lynne M Dixon; Catriona M Douglas; Shazril Imran Shaukat; Kate Garcez; Lip Wai Lee; Andrew J Sykes; David Thomson; Nicholas J Slevin
Journal:  Radiat Oncol       Date:  2017-11-14       Impact factor: 3.481

5.  Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study.

Authors:  Olgun Elicin; Ekin Ermiş; Christoph Oehler; Daniel M Aebersold; Francesca Caparrotti; Frank Zimmermann; Gabriela Studer; Guido Henke; Lukas Adam; Lukas Anschuetz; Mahmut Ozsahin; Matthias Guckenberger; Mohamed Shelan; Nuri Kaydıhan; Oliver Riesterer; Robin J D Prestwich; Thierry Spielmann; Roland Giger; Mehmet Şen
Journal:  Front Oncol       Date:  2019-09-20       Impact factor: 6.244

6.  Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer.

Authors:  Brian O'Sullivan; Shao Hui Huang; Thomas Keane; Wei Xu; Jie Su; John Waldron; Patrick Gullane; Fei-Fei Liu; Padraig Warde; David Payne; Li Tong; Bernard Cummings
Journal:  Clin Transl Radiat Oncol       Date:  2020-01-28

Review 7.  Organ preservation surgery for laryngeal cancer.

Authors:  Sharad Chawla; Andrew Simon Carney
Journal:  Head Neck Oncol       Date:  2009-05-15

8.  Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.

Authors:  M I Saunders; A Rojas; B E Lyn; K Pigott; M Powell; K Goodchild; P J Hoskin; H Phillips; N Verma
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

Review 9.  The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.

Authors:  C M van Leeuwen; A L Oei; J Crezee; A Bel; N A P Franken; L J A Stalpers; H P Kok
Journal:  Radiat Oncol       Date:  2018-05-16       Impact factor: 3.481

Review 10.  [Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].

Authors:  D Azria; C Hennequin; P Giraud
Journal:  Cancer Radiother       Date:  2020-04-10       Impact factor: 1.018

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.